UNITED LAB: Levofloxacin and Moxifloxacin Hydrochloride Eye Drops have passed the market approval

AASTOCKS
2025.12.09 09:55

UNITED LAB (03933.HK) announced that the levofloxacin eye drops and moxifloxacin hydrochloride eye drops submitted by its wholly-owned subsidiary Zhuhai United Lab Co., Ltd. Zhongshan Branch have passed the listing approval of the National Medical Products Administration of China.

The company stated that levofloxacin is a third-generation fluoroquinolone antibiotic, which can be used for the treatment of blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland dysfunction, and keratitis, as well as for sterile chemotherapy in ophthalmic perioperative care. Currently, levofloxacin eye drops are classified as Category A drugs in the National Medical Insurance Catalog (2024 edition).

Moxifloxacin hydrochloride belongs to the fourth generation of fluoroquinolone drugs and is suitable for the treatment of bacterial conjunctivitis caused by sensitive microorganisms such as Staphylococcus aureus, Haemophilus influenzae, and Chlamydia trachomatis. Currently, moxifloxacin hydrochloride eye drops are classified as Category B drugs in the National Medical Insurance Catalog (2024 edition)

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer